Juvenile Huntington's Disease FDA Patient Listening Session Summarykatie8288Apr 4, 20230 min readJoHD FDA PLS Review.pdfDownload PDF • 509KB
Prilenia has entered into a collaboration and license agreement with Ferrer for the commercialization and co-development of pridopidine in Europe and other select markets
uniQure Announces FDA Breakthrough Therapy Designation Granted to AMT-130 for the Treatment of Huntington’s Disease
Comentários